

## AMENDMENTS TO THE CLAIMS

This Listing of the Claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims

1-48. (Canceled)

49. (Previously Presented) A formulation, comprising about 100 mg of crystal form B of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride and about 5 mg of ascorbic acid in the form of a tablet.

50. (Previously Presented) The formulation of claim 49, further comprising crospovidone, dibasic calcium phosphate, D-mannitol, riboflavin and sodium stearyl fumarate.

51. (Previously Presented) The formulation of claim 49, further comprising crospovidone.

52. (Previously Presented) The formulation of claim 49, further comprising dibasic calcium phosphate.

53. (Previously Presented) The formulation of claim 49, further comprising D-mannitol.

54. (Previously Presented) The formulation of claim 49, further comprising riboflavin.

55. (Previously Presented) The formulation of claim 49, further comprising sodium stearyl fumarate.

56. (Previously Presented) A formulation, comprising crystal form B of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride and ascorbic acid in the form of a tablet, wherein the weight ratio of ascorbic acid to (6R)-L-erythro-tetrahydrobiopterin is about 1:5.5, about 1:6, about 1:6.5, about 1:7, about 1:7.5, about 1:8, about 1:8.5, about 1:9, about 1:9.5, about 1:10, about 1:10.5, about 1:11, about 1:11.5, about 1:12, about 1:12.5, about 1:13, about 1:13.5, about 1:14, about 1:14.5, about 1:15, about 1:15.5, about 1:16, about 1:16.5, about 1:17, about 1:17.5, about 1:18, about 1:18.5, about 1:19, about 1:19.5, about 1:20, about 1:20.5, about 1:21, about 1:21.5, about 1:22, about 1:22.5, about 1:23, about 1:23.5, about

1:24, about 1:24.5, about 1:25, about 1:25.5, about 1:26, about 1:26.5, about 1:27, about 1:27.5, about 1:28, about 1:28.5, about 1:29, or about 1:29.5.

57. (Previously Presented) The formulation of claim 56, further comprising crospovidone, dibasic calcium phosphate, D-mannitol, riboflavin and sodium stearyl fumarate.

58. (Previously Presented) The formulation of claim 56, further comprising crospovidone.

59. (Previously Presented) The formulation of claim 56, further comprising dibasic calcium phosphate.

60. (Previously Presented) The formulation of claim 56, further comprising D-mannitol.

61. (Previously Presented) The formulation of claim 56, further comprising riboflavin.

62. (Previously Presented) The formulation of claim 56, further comprising sodium stearyl fumarate.

63. (Previously Presented) The formulation of claim 56, wherein the weight ratio of ascorbic acid to (6R)-L-erythro-tetrahydrobiopterin is about 1:16.5, about 1:17, about 1:17.5, about 1:18, about 1:18.5, about 1:19, about 1:19.5, about 1:20, about 1:20.5, about 1:21, about 1:21.5, about 1:22, about 1:22.5, about 1:23, about 1:23.5, about 1:24, about 1:24.5, or about 1:25.

64. (Previously Presented) The formulation of claim 56, wherein the weight ratio of ascorbic acid to (6R)-L-erythro-tetrahydrobiopterin is about 1:19, about 1:19.5, or about 1:20.

65. (New) A formulation, comprising crystal form B of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride and ascorbic acid in the form of a tablet, wherein the weight ratio of ascorbic acid to (6R)-L-erythro-tetrahydrobiopterin is about 1:2, about 1:3, about 1:4, or about 1:5.

66. (New) The formulation of claim 65, further comprising crospovidone.

67. (New) The formulation of claim 65, further comprising dibasic calcium phosphate.
68. (New) The formulation of claim 65, further comprising D-mannitol.
69. (New) The formulation of claim 65, further comprising riboflavin.
70. (New) The formulation of claim 65, further comprising sodium stearyl fumarate.